<?xml version='1.0' encoding='utf-8'?>
<document id="21439816"><sentence text="Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours."><entity charOffset="44-53" id="DDI-PubMed.21439816.s1.e0" text="SU-014813" /><entity charOffset="74-83" id="DDI-PubMed.21439816.s1.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.21439816.s1.e0" e2="DDI-PubMed.21439816.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21439816.s1.e0" e2="DDI-PubMed.21439816.s1.e1" /></sentence><sentence text="In pre-clinical models enhanced anti-tumour activity was observed when SU-014813, an oral multi-targeted tyrosine kinase inhibitor was combined with docetaxel"><entity charOffset="71-80" id="DDI-PubMed.21439816.s2.e0" text="SU-014813" /><entity charOffset="105-113" id="DDI-PubMed.21439816.s2.e1" text="tyrosine" /><entity charOffset="149-158" id="DDI-PubMed.21439816.s2.e2" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.21439816.s2.e0" e2="DDI-PubMed.21439816.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21439816.s2.e0" e2="DDI-PubMed.21439816.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21439816.s2.e0" e2="DDI-PubMed.21439816.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21439816.s2.e1" e2="DDI-PubMed.21439816.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21439816.s2.e1" e2="DDI-PubMed.21439816.s2.e2" /></sentence><sentence text=" This synergy might be explained by improvement of the penetration of cytotoxic agents into tumours as a result of both VEGFR and PDGFR inhibition" /><sentence text=" We assessed the maximal tolerated dose (MTD), evaluated the pharmacokinetics and preliminary anti-tumour efficacy of oral SU-014813 administered continuously in combination with docetaxel to patients with advanced solid tumours"><entity charOffset="123-132" id="DDI-PubMed.21439816.s4.e0" text="SU-014813" /><entity charOffset="179-188" id="DDI-PubMed.21439816.s4.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.21439816.s4.e0" e2="DDI-PubMed.21439816.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21439816.s4.e0" e2="DDI-PubMed.21439816.s4.e1" /></sentence><sentence text="" /><sentence text="In this phase I study successive patient cohorts received docetaxel 60 or 75mg/m(2) every 3weeks in combination with chronic daily dosing of SU-014813"><entity charOffset="58-67" id="DDI-PubMed.21439816.s6.e0" text="docetaxel" /><entity charOffset="141-150" id="DDI-PubMed.21439816.s6.e1" text="SU-014813" /><pair ddi="false" e1="DDI-PubMed.21439816.s6.e0" e2="DDI-PubMed.21439816.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21439816.s6.e0" e2="DDI-PubMed.21439816.s6.e1" /></sentence><sentence text=" Dose limiting toxicity was assessed both in the first and second treatment cycle" /><sentence text="" /><sentence text="Twenty-five patients were entered on study of which 24 started treatment" /><sentence text=" Dose limiting toxicities were prolonged neutropenia, neutropenic fever, fatigue and diarrhoea" /><sentence text=" Other toxicities included fatigue, alopecia, nausea, vomiting, anorexia, rash, hypertension and hair discolouration" /><sentence text=" The recommended phase II dose was determined to be docetaxel 75mg/m(2) in combination with SU-014813 50mg/day"><entity charOffset="52-61" id="DDI-PubMed.21439816.s12.e0" text="docetaxel" /><entity charOffset="92-101" id="DDI-PubMed.21439816.s12.e1" text="SU-014813" /><pair ddi="false" e1="DDI-PubMed.21439816.s12.e0" e2="DDI-PubMed.21439816.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21439816.s12.e0" e2="DDI-PubMed.21439816.s12.e1" /></sentence><sentence text=" There was no clinically relevant pharmacokinetic drug-drug interaction" /><sentence text=" Two patients (8%) achieved a partial response (PR) and 7 patients (29%) had stabilisation of their disease (SD) &gt;6months, for a clinical benefit rate of 37" /><sentence text="5%" /><sentence text=" The activity observed in patients with melanoma and sunitinib refractory gastrointestinal stromal tumours (GIST) was particularly noteworthy"><entity charOffset="53-62" id="DDI-PubMed.21439816.s16.e0" text="sunitinib" /></sentence><sentence text="" /><sentence text="Oral SU-014813 50mg/day with docetaxel 75mg/m(2) is a clinically feasible regimen with a manageable safety profile and anti-tumour activity"><entity charOffset="5-14" id="DDI-PubMed.21439816.s18.e0" text="SU-014813" /><entity charOffset="29-38" id="DDI-PubMed.21439816.s18.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.21439816.s18.e0" e2="DDI-PubMed.21439816.s18.e0" /><pair ddi="false" e1="DDI-PubMed.21439816.s18.e0" e2="DDI-PubMed.21439816.s18.e1" /></sentence><sentence text=" Further development is warranted in patients with melanoma and GIST" /><sentence text="" /></document>